About Pseudouridylate synthase TRUB1
Pseudouridylate synthase TRUB1 (TRUB1) is a protein
from Homo sapiens identified by UniProt accession
Q8WWH5, 349 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Pseudouridylate synthase TRUB1 |
| UniProt accession | Q8WWH5 |
| Gene | TRUB1 |
| Organism | Homo sapiens |
| Length | 349 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- Abnormality of refraction · score 0.29
- dehydrated hereditary stomatocytosis · score 0.05
- PHF-tau measurement · score 0.05
- hemoglobin E-beta-thalassemia syndrome · score 0.05
- Adult-onset autosomal recessive sideroblastic anemia · score 0.05
- hemolytic anemia due to erythrocyte adenosine deaminase overproduction · score 0.05
- gluthathione peroxidase deficiency · score 0.04
- IRIDA syndrome · score 0.04
- Hemolytic anemia due to red cell pyruvate kinase deficiency · score 0.04
- Rh deficiency syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WWH5-F1 | alphafold | PREDICTED | 81.10 | — |
Amino-acid sequence (349 residues)
MAASEAAVVS SPSLKTDTSP VLETAGTVAA MAATPSARAA AAVVAAAART GSEARVSKAA LATKLLSLSG VFAVHKPKGP TSAELLNRLK EKLLAEAGMP SPEWTKRKKQ TLKIGHGGTL DSAARGVLVV GIGSGTKMLT SMLSGSKRYT AIGELGKATD TLDSTGRVTE EKPYDKITQE DIEGILQKFT GNIMQVPPLY SALKKDGQRL STLMKRGEVV EAKPARPVTV YSISLQKFQP PFFTLDVECG GGFYIRSLVS DIGKELSSCA NVLELTRTKQ GPFTLEEHAL PEDKWTIDDI AQSLEHCSSL FPAELALKKS KPESNEQVLS CEYITLNEPK REDDVIKTC
Explore Pseudouridylate synthase TRUB1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets